Molecular classification, based on gene expression profiling, has been a major improvement of BC approach for a decade [2, 3], with the description of five major subtypes associated with different molecular alterations and distinct clinical outcome including therapeutic response: luminal A, luminal B, ERBB2-enriched, basal and normal-like [2, 4]. This evidence concerns the gene ERBB2 and breast cancer.